- Home
- UAMY vs ESPR Comparison
UAMY vs ESPR Comparison
Compare UAMY & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- ESPR
- Stock Information
- Founded
- UAMY 1968
- ESPR 2008
- Country
- UAMY United States
- ESPR United States
- Employees
- UAMY N/A
- ESPR N/A
- Industry
- UAMY Metal Fabrications
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- ESPR Health Care
- Exchange
- UAMY Nasdaq
- ESPR Nasdaq
- Market Cap
- UAMY 251.9M
- ESPR 208.1M
- IPO Year
- UAMY N/A
- ESPR 2013
- Fundamental
- Price
- UAMY $2.46
- ESPR $0.85
- Analyst Decision
- UAMY Strong Buy
- ESPR Buy
- Analyst Count
- UAMY 4
- ESPR 7
- Target Price
- UAMY $3.38
- ESPR $5.93
- AVG Volume (30 Days)
- UAMY 3.4M
- ESPR 6.2M
- Earning Date
- UAMY 05-08-2025
- ESPR 05-06-2025
- Dividend Yield
- UAMY N/A
- ESPR N/A
- EPS Growth
- UAMY N/A
- ESPR N/A
- EPS
- UAMY N/A
- ESPR N/A
- Revenue
- UAMY $18,865,900.00
- ESPR $259,574,000.00
- Revenue This Year
- UAMY $270.45
- ESPR $4.07
- Revenue Next Year
- UAMY $104.06
- ESPR N/A
- P/E Ratio
- UAMY N/A
- ESPR N/A
- Revenue Growth
- UAMY 97.46
- ESPR 12.99
- 52 Week Low
- UAMY $0.27
- ESPR $0.69
- 52 Week High
- UAMY $3.86
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- UAMY 41.82
- ESPR 44.65
- Support Level
- UAMY $2.30
- ESPR $0.79
- Resistance Level
- UAMY $2.62
- ESPR $0.88
- Average True Range (ATR)
- UAMY 0.23
- ESPR 0.07
- MACD
- UAMY -0.06
- ESPR 0.02
- Stochastic Oscillator
- UAMY 16.67
- ESPR 69.48
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.